Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PLRX
Strong SellSinkerPliant Therapeutics, Inc. · Healthcare · United States · $69M · Avg Vol: $471K/d
12
StockRankGet insider-trade alerts
Q
24
V
36
M
27
P/E (TTM)
—
ROE
-50.3%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.7M | 1.6M | 0 | 0 | -83.7% | — | — | 3.0M | 17.4% |
| EPS | -2.94 | -2.75 | -3.47 | -2.43 | — | -1.50 | -1.43 | -1.28 | — |
| Shares | 48.9M | 59.9M | 60.9M | 61.4M | +25.6% | 61.9M | — | — | — |
| Debt | 15.8M | 11.4M | 60.2M | 29.1M | 22.5% | 28.7M | — | — | — |
| Equity | 313.3M | 473.6M | 304.1M | 181.2M | -16.7% | — | — | — | — |
| Op CF | -94.6M | -116.4M | -155.5M | -128.3M | — | -70.9M | — | — | — |
| Inv CF | -150.2M | -127.0M | 140.3M | 134.3M | — | — | — | — | — |
| Fin CF | 226.9M | 274.4M | 23.1M | -31.7M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+6.6%
SMA 50SMA 200
Close
$1.13
RSI (14)
51.4
52W High
$1.95
From 52W High
0.6%
SCORE BREAKDOWN
Quality
24
ROIC
-53.4%14.7
ROE
-50.3%18.3
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-57.1%5.7
Piotroski
29.5
Int. Cover
-50.0x5.9
D/E Ratio
0.20x50.3
Current Ratio
9.90x87.3
Value
36
P/E (TTM)
—N/A
EV/EBITDA
0.6x25.0
P/FCF
—N/A
P/B
0.5x97.2
P/S
—N/A
Div Yield
—N/A
Momentum
27
52W High %
58%33.6
RS 6M
-28%31.5
SMA 50/200
0.91x33.4
EPS Rev 4W
-59.0%0.8
EPS Rev 12W
—N/A
EPS Improve
+14%30.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$69M
P/E (Forward)
-0.9x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PLRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PLRX | Pliant Therapeutics, Inc.(you) | $69M | 12 | Strong Sell |
| ANVS | Annovis Bio, Inc. | $73M | 12 | Strong Sell |
| TENX | Tenax Therapeutics, Inc. | $80M | 12 | Strong Sell |
| HYFT | MindWalk Holdings Corp. | $65M | 14 | Strong Sell |
| MAIA | MAIA Biotechnology, Inc. | $81M | 11 | Strong Sell |
| TELO | Telomir Pharmaceuticals, Inc. | $78M | 13 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 14 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 15 | Strong Sell |
| IMA | ImageneBio, Inc. | $61M | 15 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%